Global Community

Duopharma Biotech Bhd (KLSE: DPHARMA, ticker 7148) Healthcare – Pharmaceuticals / Biotech Investment Review Recommendation: HOLD (Initiated) Key Metrics Company Overview Duopharma Biotech Bhd is a leading pharmaceutical manufacturer in Malaysia, involved in the research, development, manufacturing, and distribution of generic and specialty pharmaceutical products. Its operations span: Ethical Classic : General therapeutic generics (e.g., cardiovascular, anti-infectives) Ethical Specialty : Bio-similars for oncology, renal, and metabolic diseases Consumer Healthcare (CHC) : Notable OTC brands like Champs, Flavettes, and Uphamol As of 2025, it exports to multiple countries and operates from 3 GMP-certified manufacturing facilities.

Has raised its dividend for seven consecutive years

Has raised its dividend for three consecutive years

Has raised its dividend for four consecutive years

HOLDS MORE CASH THAN DEBT ON ITS BALANCE SHEET.

This is shaping to be a very solid company, and they won't lose anything by having ex Newcrest CEO Craig Jones as their new CEO.

Holds more cash than debt on its balance sheet

HOLDS MORE CASH THAN DEBT ON ITS BALANCE SHEET

Planet Labs leads the EO market with the largest satellite constellation, poised to capitalize on the growing demand for Earth Observation and geospatial data from companies and governments. Plunging space launch and GPU computation costs combined with advancements in CubeSat and AI technologies are boosting the utility of Earth Observation data.